Cadrenal Therapeutics Inc (CVKD): Next-Year EPS Estimate 38.08%
As of 2026-06-04, Cadrenal Therapeutics Inc (CVKD) has a next-year EPS growth estimate of 38.08%.
On 2026-05-11, analyst consensus for CVKD's next-year EPS growth shifted from 39.04% to 38.08% — a negative change of 0.96 percentage points. The revised estimate has been sustained across 19 subsequent trading sessions. Current-year growth is projected at 16.82%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 38.08%
- EPS growth this year
- 16.82%
- EPS next quarter (est)
- -$1.55
- Last price
- $4.31
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 38.08% | 16.82% | -$1.55 | $4.31 |
| 2026-06-03 | 38.08% | 16.82% | -$1.55 | $4.19 |
| 2026-06-02 | 38.08% | 16.82% | -$1.55 | $4.35 |
| 2026-06-01 | 38.08% | 16.82% | -$1.55 | $4.70 |
| 2026-05-31 | 38.08% | 16.82% | -$1.55 | $4.96 |
| 2026-05-28 | 38.08% | 16.82% | -$1.55 | $5.00 |
| 2026-05-27 | 38.08% | 16.82% | -$1.55 | $4.92 |
| 2026-05-26 | 38.08% | 16.82% | -$1.55 | $5.19 |
| 2026-05-25 | 38.08% | 16.82% | -$1.55 | $5.19 |
| 2026-05-24 | 38.08% | 16.82% | -$1.55 | $5.19 |
| 2026-05-21 | 38.08% | 16.82% | -$1.55 | $5.17 |
| 2026-05-20 | 38.08% | 16.82% | -$1.55 | $5.16 |
| 2026-05-19 | 38.08% | 16.82% | -$1.55 | $4.97 |
| 2026-05-18 | 38.08% | 16.82% | -$1.55 | $4.82 |
| 2026-05-17 | 38.08% | 16.82% | -$1.55 | $5.05 |
| 2026-05-14 | 38.08% | 16.82% | -$1.55 | $5.27 |
| 2026-05-13 | 38.08% | 16.82% | -$1.55 | $5.52 |
| 2026-05-12 | 38.08% | 16.82% | -$1.55 | $5.19 |
| 2026-05-11 | 38.08% | 16.82% | -$1.55 | $5.52 |
| 2026-05-10 | 39.04% | 15.51% | -$1.55 | $6.09 |
| 2026-05-07 | 39.04% | 15.51% | -$1.55 | $6.02 |
| 2026-05-06 | 39.04% | 15.51% | -$1.51 | $6.17 |
| 2026-05-05 | 39.04% | 15.51% | -$1.51 | $6.32 |
| 2026-05-04 | 39.04% | 15.51% | -$1.51 | $6.61 |
| 2026-05-03 | 39.04% | 15.51% | -$1.51 | $6.35 |
| 2026-04-30 | 39.04% | 15.51% | -$1.51 | $6.67 |
| 2026-04-29 | 39.04% | 15.51% | -$1.51 | $5.59 |
| 2026-04-28 | 39.04% | 15.51% | -$1.51 | $5.33 |
| 2026-04-27 | 39.04% | 15.51% | -$1.51 | $5.70 |
| 2026-04-26 | 39.04% | 15.51% | -$1.51 | $5.50 |
Recent News
- Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA MeetingGlobeNewswire
- Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA MeetingGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Cadrenal Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Cadrenal Therapeutics Inc (CVKD) has a next-year EPS growth estimate of 38.08%, based on analyst consensus.
When was the latest EPS estimate revision for CVKD?▾
The most recent revision occurred on 2026-05-11, when analysts adjusted the next-year EPS growth estimate from 39.04% to 38.08%.
What sector and industry does Cadrenal Therapeutics Inc belong to?▾
Cadrenal Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CVKD appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Cadrenal Therapeutics Inc (CVKD) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports